Scynexis (SCYX) Net Cash Flow Growth (3y) (2016 - 2026)
Scynexis (SCYX) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Scynexis | 61.87 Mn | -52.82 Mn | - | -41.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.52% |
| Mar 31, 2026 | 41.20% |
| Dec 31, 2025 | 31.68% |
| Sep 30, 2025 | 27.53% |
| Jun 30, 2025 | -45.61% |
| Mar 31, 2025 | 0.60% |
| Dec 31, 2024 | -69.83% |
| Sep 30, 2024 | 30.47% |
| Jun 30, 2024 | -35.07% |
| Mar 31, 2024 | 50.23% |
| Dec 31, 2023 | -29.22% |
| Sep 30, 2023 | -45.30% |
| Jun 30, 2023 | 31.59% |
| Mar 31, 2023 | 4.45% |
| Dec 31, 2022 | -40.15% |
| Sep 30, 2022 | -87.58% |
| Jun 30, 2022 | 55.87% |
| Mar 31, 2022 | -101.14% |
| Dec 31, 2021 | 43.30% |
| Sep 30, 2021 | -49.34% |